Analysis of whether pazopanib (Viant) is a targeted drug and its action characteristics

Pazopanib is an oral small molecule targeted drug that is a multi-target tyrosine kinase inhibitor (TKI). It mainly blocks tumor angiogenesis and tumor cell proliferation signals by inhibiting the kinase activity of multiple receptors such as vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-KIT). As a targeted drug, pazopanib can target the key driving pathways of tumors. Compared with traditional chemotherapy drugs, it is more selective and has a more controllable side effect spectrum.

The main effect of pazopanib is to simultaneously inhibit tumor angiogenesis and tumor cell proliferation. By blocking the VEGFR signaling pathway, it can reduce neovascularization, limit the nutrient and oxygen supply to tumors, and thereby inhibit tumor growth. At the same time, the inhibition of PDGFR and c-KIT can directly affect the proliferation and survival of tumor cells, making the drug effective in a variety of solid tumors, especially in advanced renal cell carcinoma (RCC) and soft tissue sarcoma.

Pazopanib has certain advantages in target selectivity, but potential adverse reactions still need to be paid attention to. Common adverse events include hypertension, abnormal liver function, diarrhea, fatigue, and rash on hands and feet. Since its metabolism mainly relies on the liver's CYP3A4enzyme system, patients need to avoid combining it with strong CYP3A4 inhibitors or inducers during use to prevent abnormal increases or decreases in blood concentration. At the same time, liver function evaluation should be carried out before use, and regular follow-up should be carried out during treatment to detect and deal with adverse reactions in a timely manner.

In addition, the dosing strategy of pazopanib emphasizes individualized management. According to the patient's constitution, tumor type and previous treatment history, doctors can adjust the starting dose or combine it with other treatments to optimize the efficacy. In clinical practice, pazopanib can be used for patients with advanced tumors who cannot tolerate traditional chemotherapy or standard targeted drugs. By precisely targeting key signaling pathways, pazopanib can inhibit tumor progression and improve patients' quality of life. Its multi-target properties and relatively good tolerability make pazopanib an important choice in the field of targeted therapy.

Reference link:https://www.drugs.com